ArticleUrologic oncology2017
Genitourinary paraganglioma: Demographic, pathologic, and clinical characteristics in the surveillance, epidemiology, and end results database (2000-2012).
Article in Urologic oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 42 citations in OpenAlex.
- Incidental intraprostatic paraganglioma: Case report and review of the literature.Urology case reports · 2026Article
- Bladder paraganglioma with lymph node metastasis treated by surgery with long-term recurrence-free survival: A case report.Urology case reports · 2026Article
- Recurrent bladder paraganglioma with peritoneal dissemination: An unusual pattern of metastatic progression. Case report and literature review.Urology case reports · 2026Article
- Case report and literature review: a case of rare papillary thyroid carcinoma combined with paraganglioma.Frontiers in oncology · 2026Article
- Bladder Paraganglioma With Rapid Metastasis: A Case Report and Review of the Literature.Cureus · 2026Article
- Muscle-Invasive Bladder Paraganglioma: Case Report and Comprehensive Literature Review.Cureus · 2025Article
- Paraganglioma of the spermatic cord: A rare tumor with unique imaging findings and diagnostic challenges.GHM open · 2025Article
- Urinary bladder paraganglioma in pregnancy: a case report and literature review.Frontiers in medicine · 2025Article
- Treatment of metastatic bladder paraganglioma with cadonilimab plus radiotherapy: a case report and literature review.Frontiers in medicine · 2025Article
- Case report: A novel somaticFrontiers in endocrinology · 2024Article
- Mass size is a major predictor of hypertensive attack during surgery in patients with paraganglioma of retroperitoneum.Translational cancer research · 2022Article
- Presentation, Management, and Outcomes of Urinary Bladder Paraganglioma: Results From a Multicenter Study.The Journal of clinical endocrinology and metabolism · 2022Article
- Nonfunctional bladder paraganglioma misdiagnosed as hemangioma: A case report.World journal of clinical cases · 2022Article
- Case Report: Octreotide plus CVD chemotherapy for the treatment of multiple metastatic paragangliomas after double resection for functional bladder paraganglioma and urothelial papilloma.Frontiers in oncology · 2022Article
- Combined thoracoscopic and laparoscopic approach to remove a large retroperitoneal compound paraganglioma: A case report.World journal of clinical cases · 2021Article
- A rare case of retroperitoneal paraganglioma located in the neck of the pancreas: a case report and literature review.Gland surgery · 2021Article
- Prognostic Nomograms for Predicting Overall Survival and Cancer-Specific Survival of Patients With Malignant Pheochromocytoma and Paraganglioma.Frontiers in endocrinology · 2021Article
- Characteristics and genetic testing outcomes of patients with clinically suspected paraganglioma/pheochromocytoma (PGL/PCC) syndrome in Singapore.Hereditary cancer in clinical practice · 2020Article
- Symptomatic paraganglioma of the urinary bladder: A rare case treated with a combined surgical approach.Urology case reports · 2020Article
- Paraganglioma of the spermatic cord: report of one case and review of literature.International journal of clinical and experimental pathology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundExtra-adrenal paragangliomas (PGLs) are infrequent, benign, and neuroendocrine tumors arising from chromaffin cells of the autonomic nervous system. Most PGLs are sporadic, but up to 32% are associated with inherited syndromes such as neurofibromatosis type 1, von Hippel-Lindau disease, and familial PGL. Although most PGLs develop above the umbilicus, they have been reported in the genitourinary (GU) tract. Owing to the paucity of literature on the rates of GU PGL, the objective of our study is to describe the demographic, pathologic, and clinical characteristics of GU PGL, and compare them to non-GU sites of PGL using the surveillance, epidemiology, and end results (SEER) database.
methodsThe SEER 18 database was used to identify all cases of PGL from 2000 to 2012. Demographic, pathologic, and clinical characteristics were described using chi-square and t-test for categorical and continuous variables, respectively. The Kaplan-Meier method was used to compare overall survival (OS) between GU and non-GU PGL. Statistical significance was defined as P<0.05. All analyses were performed using excel and SAS/Stat version 9.4.
resultsA total of 299 cases of PGL were retrieved from SEER, and 20 (6.7%) of the total PGL arose from the GU tract. The mean age at diagnosis was higher in non-GU than GU PGL (50.4±17.2 vs. 40.8±15.6, P = 0.026). Furthermore, 75% of GU PGLs developed in the bladder, followed by the kidneys/renal pelvis, and spermatic cord (20%). Non-GU PGL developed most frequently within the endocrine system (43%). PGL, overall, was more common in men than in women, and it was more common in whites than all other races. Although 55.5% of GU PGLs were organ confined, only 22.2% of non-GU PGLs were localized at diagnosis. All cases of PGL were treated with surgery. There were 2 cause-specific deaths in the GU PGL groups between 2000 and 2012. The 5-year OS was 93.3% for GU PGL vs. 65.5% in non-GU PGL (P = 0.062).
conclusionsGU PGL remains rare with low incidence (6.7% of all PGL cases) in the US population between 2000 and 2012. Bladder PGL represents just 5% of all PGL. Moreover, GU PGL had better OS compared to PGL developing outside of the GU tract although the P-value only approached statistical significance. The bladder represents the most common site of involvement, and surgery is the mainstay of treatment for GU PGL. Clearer prognostic factors, including tumor grade and stage, are needed to better elucidate PGL management in the future; thus, pooled studies from various institutions with detailed clinical information are needed to delineate these prognostic factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.